SCHEMBL4947956

SCHEMBL4947956

CCN1CCN(c2ccc(Nc3cc(NC)ncn3)cn2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 6/20 0.46
HCK P08631 1/20 0.46
BTK Q06187 1/20 0.46
FLT3 P36888 3/20 0.46
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
SYK P43405 3/20 0.42
ZAP70 P43403 1/20 0.41
METTL3 Q86U44 2/20 0.41
ABL1 P00519 3/20 0.41
BCR P11274 3/20 0.41
HDAC3 O15379 2/20 0.41
HDAC4 P56524 2/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC7 Q8WUI4 2/20 0.41
HDAC2 Q92769 2/20 0.41
HDAC10 Q969S8 2/20 0.41
HDAC11 Q96DB2 2/20 0.41
HDAC8 Q9BY41 2/20 0.41
HDAC6 Q9UBN7 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL374708 0.84 HCK (0.58) KITHCKBTKFLT3KDM4E
SCHEMBL4949665 0.83 HRH3 (0.41) HRH3WEE1
SCHEMBL15183915 0.82 KDM4E (0.52) KITFLT3KDM4EGAASYK
SCHEMBL14659640 0.79 HCK (0.43) KITHCKBTKFLT3KDM4E
SCHEMBL374474 0.79 METTL3 (0.47) KITHCKBTKFLT3KDM4E
SCHEMBL4947981 0.79 HCK (0.51) KITHCKBTKFLT3JAK2
SCHEMBL1126180 0.77 KDM1A (0.50) KITFLT3KDM4EGAASYK
SCHEMBL4949084 0.74 ABL1 (0.51) HCKABL1BCR
SCHEMBL15179045 0.74 KDM4E (0.50) KDM4EGAASYKZAP70JAK2
SCHEMBL374541 0.74 TNNI3K (0.47) KITHCKBTKFLT3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1976847-B1 PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS NOVARTIS AG (CH) 2015-06-17 EP disclosed
US-8759517-B2 Pyrirnidinyl aryl urea derivatives being FGF inhibitors NOVARTIS AG (CH) 2014-06-24 US disclosed
US-20130030171-A1 Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors NOVARTIS AG (CH) 2013-01-31 US disclosed
US-8293746-B2 Pyrimidinyl aryl urea derivatives being FGF inhibitors NOVARTIS AG (CH) 2012-10-23 US disclosed
US-20080312248-A1 Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors NOVARTIS AG 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312248-A1 Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors FGFR1, FGF1, FGF2 KIT 393/4885HCK 1180/4885BTK 269/4885
US-20130030171-A1 Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors FGFR1, FGF1, FGF2 KIT 393/4885HCK 1180/4885BTK 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.